Olanzapine Tablets, 10 mg, packaged in a) 30-count bottles (NDC 62756-554-83), b) 100-count bottl...

FDA Drug Recall #D-0701-2017 — Class III — March 22, 2017

Recall Summary

Recall Number D-0701-2017
Classification Class III — Low risk
Date Initiated March 22, 2017
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Sun Pharmaceutical Industries, Inc.
Location Cranbury, NJ
Product Type Drugs
Quantity 38,316 bottles

Product Description

Olanzapine Tablets, 10 mg, packaged in a) 30-count bottles (NDC 62756-554-83), b) 100-count bottles (NDC 62756-554-88), and c) 1000-count bottles (NDC 62756-554-18), Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, 350 Gujarat, India, NDC 62756-551-18.

Reason for Recall

Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities).

Distribution Pattern

Nationwide in the USA and Puerto Rico

Lot / Code Information

Lot #: a) JKP1354A, Exp 03/17, JKP2746A, Exp 06/17, JKR5751A, Exp 04/18; b) JKP1355A, Exp 03/17, JKP2738A, JKP3145A, Exp 06/17, JKR5476A, Exp 04/18; c) JKP1353A, Exp 03/17, JKP3146A, JKP2746B, Exp 06/17

Other Recalls from Sun Pharmaceutical Industries, Inc.

Recall # Classification Product Date
D-1032-2020 Class II Doxycycline Capsules, USP, 75 mg, 100-count bot... Mar 13, 2020
D-1033-2020 Class II Doxycycline Capsules, USP, 100 mg, 50-count bot... Mar 13, 2020
D-1047-2020 Class II Atorvastatin Calcium Tablets, USP 40 mg, Rx onl... Mar 9, 2020
D-0788-2020 Class II Testosterone Cypionate for Injection, 2,000 mg/... Jan 14, 2020
D-0787-2020 Class II Testosterone Cypionate for Injection, USP, 1,00... Jan 14, 2020

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.